Product Description
Sulbactam is in a class of medications called beta-lactamase inhibitors. It works by preventing bacteria from destroying ampicillin. (Sourced from: https://medlineplus.gov/druginfo/meds/a693021.html)
Mechanisms of Action: LACTB Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Austria | Brazil | Bulgaria | Chile | China | Colombia | Cyprus | Dominican Republic | Ecuador | Egypt | Estonia | France | Germany | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Korea | Lithuania | Malaysia | Mexico | Morocco | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Spain | Sri Lanka | Taiwan | Thailand | Turkey | Ukraine | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belarus, Brazil, China, Greece, Hungary, India, Israel, Korea, Lithuania, Mexico, Peru, Puerto Rico, Russia, Taiwan, Thailand, Turkey, United States, Unknown Location
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Acinetobacter Infections|Bacteremia|Pneumonia, Bacterial|Pneumonia, Ventilator-Associated|Respiratory Tract Infections|Urinary Tract Infections
Phase 2: Bronchiectasis|Bronchitis, Chronic|Chronic Obstructive Pulmonary Disease|Pneumonia|Pyelonephritis
Phase 1: Arthritis, Infectious|Bacteriuria|Cellulitis|Cystitis|Erysipelas|Gonorrhea|Healthy Volunteers|Lung Abscess|Meningitis, Bacterial|Osteoarthritis|Osteomyelitis|Pelvic Infection|Peritonitis|Pharyngitis|Sepsis|Sinusitis|Soft Tissue Infections|Tonsillitis|Wound Infection
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2020-001397-30 | P3 |
Active, not recruiting |
Unknown |
2024-09-03 |
|
| 2018-002526-23 | P3 |
Completed |
Acinetobacter Infections |
2021-07-26 |
|
| ATTACK | P3 |
Completed |
Bacteremia|Pneumonia, Ventilator-Associated|Pneumonia, Bacterial|Acinetobacter Infections |
2021-07-26 |
|
| CTR20130509 | P1 |
Recruiting |
Erysipelas|Pneumonia, Bacterial|Bronchiectasis|Peritonitis|Cellulitis|Bacteriuria|Pelvic Infection|Arthritis, Infectious|Bronchitis, Chronic|Sinusitis|Lung Abscess|Osteomyelitis|Osteoarthritis|Wound Infection|Pyelonephritis|Respiratory Tract Infections|Sepsis|Urinary Tract Infections|Gonorrhea|Meningitis, Bacterial|Soft Tissue Infections|Tonsillitis|Pharyngitis|Cystitis |
None |